[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355397-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355397-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","rare-gain-of-function-variants-in-idh1-and-idh2-confer-increased-risk-of-immune-mediated-rheumatic-diseases","Rare Gain-of-Function Variants in IDH1 and IDH2 Confer Increased Risk of Immune-Mediated Rheumatic Diseases","","This study investigates whether rare functional genetic variants in IDH1 and IDH2 influence immune-mediated rheumatic diseases independently of coexisting hematologic neoplasms. Gain-of-function and loss-of-function variants were identified using whole genome sequencing in UK Biobank and the All of Us Research Program, with 1:10 matching to variant-free controls. Gain-of-function variants increased incident immune-mediated rheumatic disease risk, especially polymyalgia rheumatica and rheumatoid arthritis, while loss-of-function variants showed no association.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/rare-gain-of-function-variants-in-idh1-and-idh2-confer-increased-risk-of-immune-mediated-rheumatic-diseases/355397/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/rare-gain-of-function-variants-in-idh1-and-idh2-confer-increased-risk-of-immune-mediated-rheumatic-diseases/355397.png","ImageObject",300,407,{"name":42,"@type":43},"Kyle","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary objective of this study?","Question",{"text":63,"@type":64},"To determine whether rare gain-of-function and loss-of-function genetic variants in IDH1 and IDH2 are associated with immune-mediated rheumatic diseases independently of hematologic neoplasms.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants with IDH1/IDH2 variants identified and compared?",{"text":68,"@type":64},"Gain-of-function and loss-of-function variant carriers were identified by whole genome sequencing in UK Biobank and All of Us, then matched 1:10 to controls without IDH1/IDH2 variants by age, sex, and ancestry.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings regarding gain-of-function vs loss-of-function variants?",{"text":72,"@type":64},"Gain-of-function variants in IDH1/IDH2 were associated with a higher odds of incident immune-mediated rheumatic diseases, particularly polymyalgia rheumatica and rheumatoid arthritis. Loss-of-function variants showed no association in either cohort.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355397,1790526420,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","ACR Open Rheumatology Vol. 8, No. 4, April 2026, e90034 DOI 10.1002/acr2.90034  \n© 2026 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \nRare Gain-of-Function Variants in IDH1 and IDH2 Confer Increased Risk of Immune-Mediated Rheumatic Diseases  \nMahmut S. Kaymakci, MD,1  Mehmet Hocaolu, MD,2 Kenneth J. Warrington, MD,3 and Amr H. Sawalha, MD4   \nObjective. Gain-of-function variants in IDH1 and IDH2 are enriched among individuals with coexisting myeloid neoplasms and autoimmune diseases. However, the association between IDH1/IDH2 variants and rheumatic diseases independent of hematologic neoplasms remains unclear. We investigated the association between rare gain-of-function and loss-of-function genetic variants in IDH1 and IDH2 and immune-mediated rheumatic diseases.  \nMethods. Individuals with gain-of-function and loss-of-function variants in IDH1/IDH2 were identiﬁed by whole genome sequencing in the UK Biobank and the All of Us Research Program. These individuals were matched 1:10 to controls without IDH1 or IDH2 variants by age, sex, and ancestry. The frequency of immune-mediated rheumatic diseases in the presence and absence of IDH1/IDH2 variants was compared using chi-square or Fisher exact tests.  \nResults. Fifty-ﬁve individuals with IDH1 or IDH2 gain-of-function variants without pre-existing hematologic neoplasms were identiﬁed in the UK Biobank. These individuals had a signiﬁcantly higher frequency of incident immunemediated rheumatic diseases compared to matched controls (11 of 55 [20%] vs 20 of 550 [4%], odds ratio [OR] = 6 .6, P = 2 .7 × 10−5), mainly polymyalgia rheumatica (6 of 11) and rheumatoid arthritis (5 of 11) . Replication in the All of Us cohort identiﬁed 65 individuals with gain-of-function variants and conﬁrmed an increased odds of incident immune-mediated rheumatic diseases compared to controls (OR = 7 .7, P \u003C 5 × 10−4), predominantly rheumatoid arthritis. There was no association between loss-of-function variants in IDH1/IDH2 and immune-mediated rheumatic diseases in either cohort.  \nConclusion. Rare gain-of-function variants in IDH1/IDH2 are associated with increased risk of immune-mediated rheumatic diseases, particularly rheumatoid arthritis and polymyalgia rheumatica.  \nINTRODUCTION  \nIsocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) catalyze the conversion of isocitrate to α-ketoglutarate, a metabolite that plays a central role in epigenetic regulation.1 Gain-of-function mutations at IDH1 R132 as well as IDH2 R140 and R172 result in the accumulation of the oncometabolite (R)-2-hydroxyglutarate2 and lead to DNA and histone hypermethylation, cell differentiation blockage,3 and alterations in the immune system, such as innate immune system activation.4  \nSomatic hotspot gain-of-function mutations in IDH1 and IDH2 have been shown to be implicated in various types of cancers in humans, including myeloid neoplasms.2 These mutations  \nSupported by the Rheumatology Research Foundation’s Dr. Ephraim P. Engleman Resident Research Preceptorship Award (to Dr Kaymakci) .  \n1Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 2Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 3Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota; 4Departments of Pediatrics, Medicine, and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.  \nare also observed in clonal hematopoiesis of indeterminate potential (CHIP), a precursor state for hematologic neoplasms characterized by somatic mutations","cbCaihZ5xWqyfxH3","https://ap.wps.com/l/cbCaihZ5xWqyfxH3","pdf",242208,"English","# Objective\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What was the primary objective of this study?\",\"answer\":\"To determine whether rare gain-of-function and loss-of-function genetic variants in IDH1 and IDH2 are associated with immune-mediated rheumatic diseases independently of hematologic neoplasms.\"},{\"question\":\"How were participants with IDH1/IDH2 variants identified and compared?\",\"answer\":\"Gain-of-function and loss-of-function variant carriers were identified by whole genome sequencing in UK Biobank and All of Us, then matched 1:10 to controls without IDH1/IDH2 variants by age, sex, and ancestry.\"},{\"question\":\"What were the key findings regarding gain-of-function vs loss-of-function variants?\",\"answer\":\"Gain-of-function variants in IDH1/IDH2 were associated with a higher odds of incident immune-mediated rheumatic diseases, particularly polymyalgia rheumatica and rheumatoid arthritis. Loss-of-function variants showed no association in either cohort.\"}]","Rare Gain-of-Function Variants in IDH1 and IDH2 Confer Increased Risk of Immune-Mediated Rheumatic Diseases | PDF",1790118488,15,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a419d9fa6a05911799e509f9d6459bc9.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1d81ec792cbcd89a55941f5a9ba074f.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50436b8e062e4b7dbe78e6d9a272ee43.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34e02d470906ab0bbe9a7c7eed62d5e6.webp",980,1268]